Clinical trial
Bryostatin 1 Plus Cisplatin in Treating Patients With Metastatic or Unresectable…
NCT00003132 · NYU Langone Health, Other · Completed
Key facts
| NCT number | NCT00003132 |
|---|---|
| Title | Bryostatin 1 Plus Cisplatin in Treating Patients With Metastatic or Unresectable Cancer |
| Official title | Phase I Study of Bryostatin-1 (NSC 339555) and Cisplatin in Advanced Malignancies |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | bryostatin 1, cisplatin |
| Start date | Jan 1, 1998 |
| Primary completion | Nov 1, 2001 |
| First posted | Apr 7, 2004 |
| Last update posted | Nov 9, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: